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ABSTRACT
Background The impact of COVID-19 and ensuing 
national lockdown on asthma exacerbations is unclear.
Methods We conducted an interrupted time- series 
(lockdown on 23 March 2020 as point of interruption) 
analysis in asthma cohort identified using a validated 
algorithm from a national- level primary care database, 
the Optimum Patient Care Database. We derived asthma 
exacerbation rates for every week and compared 
exacerbation rates in the period: January to August 
2020 with a pre- COVID-19 period and January to 
August 2016–2019. Exacerbations were defined as 
asthma- related hospital attendance/admission (including 
accident and emergency visit), or an acute course of oral 
corticosteroids with evidence of respiratory review, as 
recorded in primary care. We used a generalised least 
squares modelling approach and stratified the analyses 
by age, sex, English region and healthcare setting.
Results From a database of 9 949 387 patients, there 
were 100 165 patients with asthma who experienced 
at least one exacerbation during 2016–2020. Of 278 
996 exacerbation episodes, 49 938 (17.9%) required 
hospital visit. Comparing pre- lockdown to post- lockdown 
period, we observed a statistically significant reduction 
in the level (−0.196 episodes per person- year; p<0.001; 
almost 20 episodes for every 100 patients with asthma 
per year) of exacerbation rates across all patients. The 
reductions in level in stratified analyses were: 0.005–
0.244 (healthcare setting, only those without hospital 
attendance/admission were significant), 0.210–0.277 
(sex), 0.159–0.367 (age), 0.068–0.590 (region).
Conclusions There has been a significant reduction 
in attendance to primary care for asthma exacerbations 
during the pandemic. This reduction was observed in 
all age groups, both sexes and across most regions in 
England.
INTRODUCTION
Early studies from Wuhan City (China), where 
COVID-19 caused by SARS- CoV-2 was first identi-
fied in December 2019, suggested that COVID-19 
can lead to severe pneumonia and life- threatening 
acute respiratory distress syndrome.1 These initial 
investigations also demonstrated that people with 
underlying health conditions, including respira-
tory illnesses, are at higher risk of severe disease 
and death due to COVID-19.2 These findings were 
further corroborated by studies in the USA,3 4 UK5 6 
and other European countries.7
Asthma has been identified as a possible risk 
factor for COVID-19- associated hospitalisation and 
death.3 6 A significant proportion of asthma- related 
healthcare resource utilisation and cost is associated 
with asthma exacerbations.8 Overall, asthma exac-
erbations represent a huge socioeconomic burden 
both in the UK and across the world. In the UK 
alone, there are at least 6.3 million primary care 
consultations, 93 000 hospital episodes and 1400 
deaths attributed to asthma every year.9
Since the majority of asthma exacerbations are asso-
ciated with respiratory viral illnesses,10 there was initial 
concern that COVID-19 may lead to increased asthma 
exacerbations.11 However, the evidence to date is not 
clear. A study from Wuhan reported that only 0.9% 
patient among the 269 severe cases investigated had 
asthma.12 Another study from Paris (France) reported 
that patients with asthma were not over- represented 
among the 768 hospitalised patients with COVID-19.13 
Key messages
What is the key question?
 ► What is the impact of COVID-19 and the 
ensuing national lockdown on healthcare 
attendance for asthma exacerbations?
What is the bottom line?
 ► Our national- level, interrupted- time series 
study following a cohort of 100 165 patients 
with asthma across England showed that there 
was a substantial reduction in overall primary 
care- recorded exacerbation rates for both 
men and women, in all age groups and across 
most regions in England. This reduction was 
observed in exacerbations managed in primary 
care that did not require a hospital visit. Our 
study found no significant change in more 
serious exacerbations that required hospital 
attendances and/or admission.
Why read on?
 ► Existing evidence suggests that having a 
comorbidity such as asthma is a risk factor of 
COVID-19- related hospitalisation and possibly 
death. However, the impact of the pandemic 
and the ensuing national lockdown on asthma 
exacerbations is not clear. This study provides 
national- level insights about the impact of 
national lockdown measures on healthcare 
attendance for asthma exacerbations.
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However, some studies have suggested that the percentage of patients 
who have asthma among patients with COVID-19 who are hospital-
ised is higher than asthma prevalence.14 15 In the largest population- 
based risk prediction modelling study to date, asthma has been found 
to be an independent risk factor for COVID-19 hospitalisations, but 
not death.16
The WHO declared COVID-19 a pandemic on 11 March 
2020,17 which triggered unprecedented nationally enforced 
social distancing measures by governments across the globe. 
These measures included widespread lockdowns of whole soci-
eties, including school closures and movement restrictions18 
that have had numerous negative health, social and economic 
effects.19–22 These lockdowns have however had the beneficial 
effects of leading to improvements in air quality23–25 and a likely 
reduction in circulating respiratory viruses (especially in children 
and young people). It is also possible that the earlier concerns 
about increased risk of severe illness and death from COVID-19 
may have led to improved self- management and shielding among 
patients with asthma. Consequently, we hypothesised that the 
UK’s national lockdown, which began on 23 March 2020, lead 
to a reduction in asthma exacerbations in England. We tested our 
hypothesis by following a large cohort of patients with asthma 
using a national- level primary care database.
METHODS
Data source and setting
We used the Optimum Patient Care Database (OPCRD), a live and 
growing database of de- identified, longitudinal electronic medical 
records populated by a network of primary care practices from 
across the UK. OPCRD has been used to conduct epidemiological, 
pharmaceutical and clinical studies (https:// opcrd. co. uk/).26 27 At the 
time of data access, OPCRD consisted of almost 10 million patients 
from 792 practices. We used data from the 670 practices in England 
(the remaining practices were from other nations of the UK). In 
addition to demographic information, the OPCRD dataset contains 
diagnoses, symptoms, treatment and prescription data encoded with 
Read codes, a comprehensive system of clinical concepts classifica-
tion system that has been used in primary care practices across the 
UK for about three decades.28 For this study, we were provided with 
a secure access to the Microsoft SQL database through a secure 
remote access.
Study design and population
We identified a cohort of patients with clinician diagnosed and 
recorded asthma who were then followed over time to assess if 
and when they experienced asthma exacerbations. The cohort of 
patients with asthma was identified with a previously validated 
algorithm29 over the period 1 January 2010 to 31 December 
2015. This algorithm comprised of 121 specific asthma codes 
that have previously been shown to identify patients with asthma 
from UK primary care records with high accuracy.29 The cohort 
of patients with asthma was then followed from 1 January 2016 
to 16 August 2020; and the outcome measure, asthma exacer-
bations, was determined for every patient for each week. Using 
this cohort of patients, we designed an interrupted time- series 
study with control. The follow- up period was divided into a 
COVID-19 year (the ‘intervention’ period) and pre- COVID-19 
years (the ‘control’ period). The single point intervention was 
the week corresponding to imposition of lockdown (23 March 
2020); the control was the mean weekly exacerbation rate (mean 
of 4 years, 2016–2019 inclusive for January–August), and the 
intervention period was the weekly exacerbation rate from 
January to August 2020.
Ascertainment of outcome
Based on the American Thoracic Society/European Respira-
tory Society Task Force definition30 and previously validated in 
OPCRD,31 an asthma exacerbation in a given assessment period 
was defined as the presence of either one of the following: an 
asthma- related accidental and emergency (A&E) department 
attendance, an asthma- related hospital admission or an acute 
course of oral corticosteroids (OCS) with evidence of respiratory 
review within 2 weeks of OCS prescription. In addition to Read 
codes associated with asthma- associated hospital attendance or 
admission, we identified additional non- asthma- specific hospi-
talisation codes and considered a patient to have experienced 
a hospital- associated asthma exacerbation if a patient had any 
of the 121 specific asthma codes (previously used to identify 
patients with asthma29) on the same day when they had any 
hospitalisation code in their records. Online supplemental 
appendix 1 provides a list of the Read codes used to ascertain 
the outcome.
Data analysis
For every assessment period (defined as a week), we determined 
the total number of exacerbations, normalised this number with 
the total number of patients in the study in every period and then 
converted it into an exacerbation rate (total number of exacerba-
tion episodes per patient- year). Once the exacerbation rate was 
derived for every week from January 2016 to August 2020, the 
data were split into a COVID-19 year and pre- COVID-19 years. 
In 2020, the pre- lockdown period corresponded to weeks 1–12 
(January–March), and the post- lockdown period corresponded 
to the period starting from week 13 (week starting 23 March). 
Every year in the follow- up (2016–2019) was divided into two 
periods (weeks 1–12 and weeks 13–32) to allow a comparison 
of those years with the year 2020 when the national lockdown 
was imposed. Data were then analysed using an interrupted 
time- series design with control. First, ordinary least squares 
regression (OLS) analysis was applied with eight coefficients to 
be determined. The eight coefficients were: an intercept term 
and existing trend; existing level and trend difference; post- 
intervention level and trend; and level change and trend change 
difference. The OLS model was then tested for the presence of 
‘autoregression’ and ‘regression’ type relationships in the data 
(autocorrelation type relationships are expected in data with 
seasonality pattern) with autocorrelation and partial autocor-
relation plots. This step also helped to determine the order of 
moving average and/or autoregression relationship in the data. 
Subsequently, a generalised least squares model was fitted to the 
data incorporating both the autoregression and moving average 
relationship in the data. The final fitted model was then used 
to extract the absolute and relative changes in the outcome of 
interest. In our study, the outcomes of interest were overall exac-
erbations, exacerbations that were resolved within primary care 
without any hospital visit, exacerbations that required a hospital 
visit, and overall exacerbation stratified by age groups, sex and 
region. Interrupted time- series analysis allows us to measure two 
potential changes that could occur because of the intervention: 
a change in level and a change in trend. Change in level corre-
sponds to the sudden change in the exacerbation rate immedi-
ately after the intervention. A change in trend corresponds to 
difference in the trend (slow change of exacerbation rate over 
time) between pre- intervention and post- intervention periods.
All analyses were undertaken in R Studio (V.1.2.5033) 
using R (V.3.6.2). The tidyverse packages32 were used for data 
manipulation (dplyr), date manipulations (lubridate) and data 
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visualisations (ggplot2). The nlme package33 was used for 
building the generalised least squares model. The final figures 
illustrating the results of the interrupted time series were plotted 
with Matlab (R2018a, Mathworks, USA).34
Study reporting
This study is reported following the recommendations of 
Reporting of studies Conducted using Observational Routinely- 
collected Data.35
RESULTS
Baseline characteristics of the study population
Out of the 571 166 patients with asthma identified (5.7% of 
the total population in OPCRD), 100 165 patients (17.5% of 
those identified with asthma) had at least one exacerbation 
during the follow- up period (January 2016–August 2020). The 
total follow- up time in the study was 416 639 patient- years 
(mean follow- up of 4.16 patient- years). Figure 1 provides a flow 
diagram of the patients in the study. There were more women 
(60 360; 60.1%) than men (39 673; 39.6%) with a small number 
with missing sex information (132; 0.1%). Most patients in the 
study were those aged 18–54 (43 740; 43.7%) and ≥55 years 
(44 279; 44.2%). The number of young patients with asthma 
was relatively low: 0–5 years (1407; 1.4%), 5–18 years (10 739; 
10.7%). A large proportion of the patients in the cohort were 
from East England (21 002; 21%), South East (20 445; 20.4%) 
and Yorkshire and the Humber (17 240; 17.2%). The remaining 
patients were from East Midlands (4483; 4.5%), London (3302; 
3.3%), North East (4985; 5.0%), North West (12 456; 12.4%), 
South West (14 378; 14.4%) and West Midlands (1874; 1.9%).
Exacerbation pattern during follow-up
Figure 2 provides the mean exacerbation rate of the patient 
cohort for every week during the follow- up period (January 
2016–August 2020) categorised by whether patients were 
Figure 1 Overall flow diagram of patients in the study. OPCRD, 
Optimum Patient Care Database.
Figure 2 Mean exacerbation rate for every week, from January 2016 to August 2020 across England stratified by exacerbation type: (A) primary 
care- based exacerbations only and (B) hospital- based exacerbations only.
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managed by general practitioners (GPs) only (termed primary 
care based in the figure) or whether patients eventually attended 
hospital (termed hospital based in the figure, which included 
both A&E attendance and hospital admission). The figure 
illustrates the seasonality pattern in both categories: the exac-
erbation rate gradually decreased from January onwards until 
summer, and it then gradually increased again from August/
September until December/January. The sharp decrease during 
the last week of December corresponded to restricted opening 
times of primary care practices. Online supplemental appendix 2 
provides the mean exacerbation rate of all patients in the cohort 
during follow- up categorised by sex (online supplemental figure 
S1), age (online supplemental figure S2) and region (online 
supplemental figure S3).
During follow- up, there were a total of 278 996 exacerbation 
episodes experienced by the 100 165 patients. Of these, 229 
058 (82.1%) were managed exclusively in primary care without 
requiring any hospital visit, and the remaining 49 938 (17.9%) 
required a hospital visit. Table 1 provides the mean exacerbation 
rate for the patients in the cohort in two distinct periods: weeks 
1–12 and 13–32. There was a significant drop in the mean exac-
erbation rate for all years during the follow- up when comparing 
weeks 1–12 (corresponding to January–March) with weeks 
13–32 (corresponding to April–August).
Interrupted time-series analyses
Table 2 provides results of the interrupted time- series analyses 
(the rates in this table express the number of exacerbations per 
person- year). The intercept (akin to a mean value when trend 
and change due to intervention is separately accounted for) in 
the table shows that: there were more exacerbations that did not 
require hospital attendance/admission and were resolved within 
primary care compared with those that required hospital atten-
dance/admission (0.913 vs 0.134); overall, women were slightly 
more likely to experience exacerbations than men (1.090 vs 
0.976); and the exacerbation rate was highest in the ≥55 age 
group (1.305) followed by 18–54 (0.919) and 0–5 (0.839) 
and lowest in 5–17 (0.618). Based on regions in England (as 
represented in OPCRD), West Midlands had the highest rate of 
exacerbation (1.383) followed by the North East (1.205), while 
London had the lowest rate of exacerbation (0.639).
Overall, there was a statistically significant change in level 
(−0.196; p=0.008) of exacerbation rate. The change in trend 
was, however, not significant (0.029; p=0.054). When exac-
erbations were categorised into whether they were managed 
exclusively in primary care with no need of hospital attendance 
and/or admission, or whether they required hospital visit, we 
only found a statistically significant difference in level (−0.244; 
p=0.000) and trend (−0.022; p=0.000) in the former case. 
Figure 2 shows mean exacerbation rate for every week, from 
January 2016 to August 2020 across England stratified by exac-
erbation type: (a) primary care- based exacerbations only and (b) 
hospital- based exacerbations only.
Figure 3 illustrates the result of the interrupted time- series 
analyses for both of these categories. Table 2 provides results of 
the interrupted time- series analyses when the cohort was strati-
fied by sex, age and region. Stratified by sex, there is a significant 
reduction in trend and level for both men and women. Stratified 
by age, there was a significant drop in all groups with the most 
notable decrease in the youngest age group (aged 5–10 years in 
2020). When stratified by region, there was a significant drop in 
level across all regions except London and the North East.
DISCUSSION
We found a significant overall decrease in asthma exacerba-
tions in England during the COVID-19 pandemic after the 
lockdown was imposed on 23 March 2020. The decrease 
was statistically significant in all age groups, in both men 
and women, and almost across all regions in England. The 
primary care dataset allowed us to assess whether a given 
exacerbation episode was resolved within primary care or 
whether it required a hospital visit. Throughout follow- up 
(January 2016–August 2020), most asthma exacerbations 
were resolved within primary care without requiring any 
hospital visit. We found a statistically significant drop in 
exacerbation episodes that did not require hospital visit, 
after the lockdown was imposed. There was no significant 
decrease in exacerbation episodes that required hospital 
visit. Overall, our findings indicate that there was a substan-
tial decrease in asthma exacerbations that did not require 
hospital visit (likely mild cases), but insufficient evidence to 
suggest any impact on those (presumably more severe) cases 
of asthma exacerbations that required a hospital visit.
To our knowledge, this is the first national- level study that 
assessed the impact of the COVID-19 pandemic on atten-
dance to primary or secondary care for asthma exacerbations. 
Table 1 Total number of patients and exacerbation rate over time (mean rates for each period given, weeks refer to ISO weeks)
Exacerbation rate (number of episodes/person- year)
mean (95% CI)
Period Number of patients in cohort Resolved within primary care only Required hospital visit Overall
2016 (weeks 1–12) 100 165 0.82 (0.76 to 0.87) 0.11 (0.10 to 0.11) 0.92 (0.87 to 0.98)
2016 (weeks 13–32) 99 813 0.52 (0.49 to 0.55) 0.10 (0.09 to 0.10) 0.61 (0.58 to 0.64)
2017 (weeks 1–12) 98 264 0.71 (0.62 to 0.80) 0.13 (0.12 to 0.14) 0.84 (0.75 to 0.93)
2017 (weeks 13–32) 97 689 0.46 (0.43 to 0.48) 0.10 (0.09 to 0.11) 0.56 (0.53 to 0.58)
2018 (weeks 1–12) 96 012 0.73 (0.64 to 0.82) 0.15 (0.13 to 0.16) 0.88 (0.79 to 0.97)
2018 (weeks 13–32) 95 410 0.43 (0.40 to 0.45) 0.13 (0.12 to 0.13) 0.55 (0.53 to 0.57)
2019 (weeks 1–12) 91 439 0.62 (0.55 to 0.68) 0.14 (0.13 to 0.15) 0.75 (0.68 to 0.82)
2019 (weeks 13–32) 88 976 0.41 (0.38 to 0.44) 0.10 (0.10 to 0.11) 0.51 (0.48 to 0.54)
2020 (weeks 1–12) 77 258 0.63 (0.59 to 0.67) 0.16 (0.14 to 0.17) 0.78 (0.74 to 0.83)
2020 (weeks 13–32) 67 995 0.23 (0.20 to 0.25) 0.10 (0.09 to 0.11) 0.33 (0.30 to 0.35)
Total number of exacerbation episodes: 278 996; exacerbation episodes managed exclusively by a general practitioner: 229 058 (82.1%); exacerbation episodes requiring 
hospital visit: 49 938 (17.9%).
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Table 2 Intercept, residual SE, and change in level and trend after lockdown was imposed with corresponding p values (compared with average of 
last 4 years, the control group)
Cohort Intercept Change in level after intervention Change in trend after intervention Residual SE
All patients, n=100 165 0.833* −0.196 (0.0077) 0.029 (0.0536) 0.082
Stratification by healthcare setting
  Resolved within primary care 0.913* −0.244* −0.022 (0.0001) 0.032
  Hospital 0.134* −0.005 (0.7894) 0.004 (0.1149) 0.014
Stratification of population cohort by sex†
  Men, n=39 673 0.976* −0.210* −0.009 (0.0068) 0.035
  Women, n=60 360 1.090* −0.277* −0.024 (0.0015) 0.042
Stratification of population cohort by age (years)
  0–5, n=1407 0.839* −0.367 (0.0013) −0.009 (0.5175) 0.127
  5–17, n=10 739 0.618* −0.159 (0.0328) −0.005 (0.6351) 0.061
  18–54, n=43 740 0.919* −0.238 (0.0010) −0.037 (0.0004) 0.059
  ≥55, n=44 279 1.305* −0.241* 0.002 (0.7942) 0.041
Stratification of population cohort by region
  East England, n=21 002 1.067* −0.283* −0.014 (0.0307) 0.048
  East Midlands, n=4483 0.787* −0.371* −0.037 (0.0003) 0.083
  London, n=3302 0.639* −0.261 (0.0702) −0.004 (0.8451) 0.133
  North East, n=4985 1.205* −0.068 (0.6176) −0.025 (0.1845) 0.108
  North West, n=12 456 1.186* −0.258 (0.0147) −0.060 (0.0001) 0.089
  South East, n=20 445 1.030* −0.261* 0.000 (0.9582) 0.051
  South West, n=14 378 1.049* −0.275* −0.010 (0.0028) 0.050
  West Midlands, n=1874 1.383* −0.590 (0.0031) −0.146* 0.191
  Yorkshire and the Humber, n=17 240 0.989* −0.132 (0.0235) −0.011 (0.1555) 0.048
*P<0.0001.
†A total of 132 patients did not have sex information in the database.
Figure 3 Interrupted time- series (ITS) model fitted to yearly exacerbation rate for every week from January to August for control group (mean 
rate from 2016 to 2019) and the intervention group (2020): (A) exacerbations related to primary care consultations only and (B) hospital- based 
exacerbations only.
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The key strengths of this study are a long follow- up (January 
2016–August 2020), and the use of validated algorithms 
to identify patients with asthma and asthma exacerbations 
in a national primary care database from multiple centres 
covering a wide geographical area. This study used all 
English data in the OPCRD that were collected as part of 
routine clinical care pathway thereby minimising both selec-
tion and information bias often associated with observa-
tional studies.36
There are some limitations to our study. We only had 
access to primary care records and while primary care will 
be the first point of contact for any patient with asthma, it is 
likely that some patients might have attended A&E depart-
ment in hospital without referral. Our study may miss any 
such episodes, particularly if there is no subsequent primary 
care follow- up by the patient or if there is no communica-
tion between primary and secondary care. While it is not 
possible to ascertain the number of such episodes due to 
absence of any linked data (to link primary care records 
with A&E), we believe that such occurrences will be rare 
since patients with chronic condition (such as asthma) are 
likely to make contact with primary care for follow- up and/
or medication. In addition, a discharge letter is typically 
sent to primary care following any hospital discharge which 
then gets added to a patient’s primary care record. Second, 
while interrupted time- series analyses quantitatively show 
the extent of difference observed after an intervention, it 
cannot ascertain any causal relationships. Lastly, we have 
assumed that the approach of GPs in using the Read codes 
to manage patients with asthma has not changed during the 
pandemic.
It is important to highlight that our analysis included all 
patients with asthma who had at least one exacerbation during 
the follow- up period. While we could include all patients in 
the analysis, it will not change the results of the interrupted 
time- series analysis. This is because these excluded patients 
had zero exacerbation episodes and therefore the relative 
change in exacerbation rate from pre- COVID-19 years to 
COVID-19 years will not change (only the absolute value of 
the exacerbation rate, and hence the intercept value in the 
interrupted time- series analysis will change across the whole 
time series).
Since viral respiratory infections are the main trigger of 
asthma exacerbations,10 there were concerns at the start of 
the pandemic that COVID-19 may have led to increase in 
asthma exacerbations and that COVID-19 outcomes would 
be poorer in those with asthma. Several studies, to date, 
have investigated COVID-19 outcomes in patients with 
asthma.13 16 18 19 21 25 33 However, to date, the impact of the 
pandemic on asthma exacerbations is unclear. A recent study 
by Public Health England investigating causes of excess 
public deaths found a reduction in respiratory- related deaths 
(acute respiratory infections, chronic lower respiratory 
diseases and other respiratory diseases) during the pandemic 
when compared with deaths from the previous 5 years in 
England.37 Another recent study that aimed to derive and 
validate a risk prediction algorithm to estimate COVID-19 
outcomes found that asthma does not increase risk of dying 
in either men or women, and only marginally increases the 
risk hospitalisation.16 These recent results support a reas-
suring viewpoint that patients with asthma are, perhaps, 
not as high risk as initially feared, and these studies align 
with our results that suggest an overall decrease in asthma 
exacerbations.
One possible explanation for a significant decrease only 
in exacerbation episodes that did not require hospital visit 
could be due to a change in careseeking behaviour. Some 
patients may have preferred exacerbating at home rather 
than reporting to primary care for fear of COVID-19 and a 
subset of those patients whose exacerbation did not resolve 
at home ended up visiting hospital for their asthma. It is also 
possible that some patients may have preferred self- referring 
themselves to A&E, as opposed to contacting primary care, 
so that they could be seen in person (in response to the 
pandemic, there was a shift from in- person to remote consul-
tations in primary care across the UK38). However, by and 
large, there was an overall decrease in asthma exacerbations 
and while our study cannot definitively prove the reasons 
for this decrease, we believe that a combination of factors 
led to a reduction in asthma exacerbations. These factors 
include changing behaviour due to lockdown measures 
leading to reduction in air pollution, reduced circulation 
of respiratory viruses, improved self- management driven by 
patient concerns during the pandemic39 and shielding by a 
subset of patients (government- introduced UK- wide scheme 
where high- risk individuals are contacted and advised to 
follow stricter restrictions than the rest of the population40). 
We cannot, however, ascertain the role, if any, and extent 
of these factors in the current study. There is now a need 
to undertake further research (surveys of patient’s attitudes, 
and qualitative interviews with patients and primary care 
health professionals) to understand the social and disease- 
related mechanisms that can help explain our findings.
CONCLUSION
Our study, the largest cohort study assessing the impact of 
COVID-19 on asthma to date, showed that there has been 
a significant reduction in asthma exacerbations (as recorded 
in primary care) during the pandemic and this reduction was 
observed in all age groups, both men and women and across 
most regions in England. This reduction in exacerbation rate 
was mainly seen in relation to exacerbations resolved within 
primary care without a need for a hospital visit. There is a 
need for further work to investigate the factors responsible 
for this decrease.
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